Arcellx, Inc. (NASDAQ: ACLX) reported that Michelle Gilson, the company’s Chief Financial Officer, sold 11,291 shares of Arcellx common stock on February 17, 2026, with the combined transactions valued at approximately $784,782.
The disposition occurred in two separate trades. In the first, Gilson sold 7,141 shares at a weighted average price of $69.2103, with executed prices spanning from $68.69 to $69.68. The second transaction comprised 4,150 shares sold at a weighted average price of $70.0125, with prices in that block ranging from $69.69 to $70.55.
These sales follow an acquisition earlier in the year: on January 2, 2026, Gilson obtained 20,496 shares of Arcellx common stock through the exercise of restricted stock units at a per-share cost of $0.
Analyst activity and program updates
Arcellx has also been the subject of multiple analyst actions and research notes. Rothschild Redburn revised its rating on the company, moving from Buy to Neutral and lowering its price target from $113.00 to $82.00, citing concerns about competition.
In contrast, Stifel retained a Buy rating and set a price target of $127.00, pointing to encouraging safety findings from in vitro work on Arcellx’s anito-cel candidate. Company disclosures indicate that the D-Domain binder used in anito-cel exhibited no tonic signaling or off-target activity in preclinical tests, a detail that was cited as supportive of a favorable safety profile for the CAR T approach.
Arcellx said it intends to present additional data on anito-cel at the 2026 Tandem Meetings, with the forthcoming material expected to address the therapy’s ability to clear tumor cells without engendering prolonged inflammation.
Adding to the coverage mix, UBS initiated coverage of Arcellx with a Buy rating and a $100.00 price target, noting the company’s potential to enter the relapsed/refractory multiple myeloma market by 2026.
Context and takeaway
The combination of an insider sale, a prior personal share acquisition via RSU exercise, and a range of analyst opinions frames a nuanced picture: investors and coverage analysts are parsing encouraging preclinical safety signals alongside worries about a competitive therapeutic landscape. The company’s upcoming presentations at industry meetings will provide further data to evaluate anito-cel’s profile.